Literature DB >> 23776144

The prostanoid EP4 receptor and its signaling pathway.

Utako Yokoyama1, Kousaku Iwatsubo, Masanari Umemura, Takayuki Fujita, Yoshihiro Ishikawa.   

Abstract

The EP4 prostanoid receptor is one of four receptor subtypes for prostaglandin E2. It belongs to the family of G protein-coupled receptors. It was originally identified, similar to the EP2 receptor as a G(s)α-coupled, adenylyl cyclase-stimulating receptor. EP4 signaling plays a variety of roles through cAMP effectors, i.e., protein kinase A and exchange protein activated by cAMP. However, emerging evidence from studies using pharmacological approaches and genetically modified mice suggests that EP4, unlike EP2, can also be coupled to G(i)α, phosphatidylinositol 3-kinase, β-arrestin, or β-catenin. These signaling pathways constitute unique roles for the EP4 receptor. EP4 is widely distributed in the body and thus plays various physiologic and pathophysiologic roles. In particular, EP4 signaling is closely related to carcinogenesis, cardiac hypertrophy, vasodilation, vascular remodeling, bone remodeling, gastrointestinal homeostasis, renal function, and female reproductive function. In addition to the classic anti-inflammatory action of EP4 on mononuclear cells and T cells, recent evidence has shown that EP4 signaling contributes to proinflammatory action as well. The aim of this review is to present current findings on the biologic functions of the EP4 receptor. In particular, we will discuss its diversity from the standpoint of EP4-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23776144     DOI: 10.1124/pr.112.007195

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  85 in total

1.  Characterization of Eicosanoids Produced by Adipocyte Lipolysis: IMPLICATION OF CYCLOOXYGENASE-2 IN ADIPOSE INFLAMMATION.

Authors:  Allison Gartung; Jiawei Zhao; Simon Chen; Emilio Mottillo; Garrett C VanHecke; Young-Hoon Ahn; Krishna Rao Maddipati; Andrey Sorokin; James Granneman; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2016-05-31       Impact factor: 5.157

2.  Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.

Authors:  Liao Sun; Xiaohong Wei; Xueting Liu; Danli Zhou; Fang Hu; Yingjuan Zeng; Ying Sun; Shunkui Luo; Yu Zhang; Xian Ping Yi
Journal:  Tumour Biol       Date:  2015-10-28

3.  Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1.

Authors:  Kirsten M Hooper; Jui-Hung Yen; Weimin Kong; Kate M Rahbari; Ping-Chang Kuo; Ana M Gamero; Doina Ganea
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

4.  Endogenous prostaglandin E2 amplifies IL-33 production by macrophages through an E prostanoid (EP)2/EP4-cAMP-EPAC-dependent pathway.

Authors:  Sachin K Samuchiwal; Barbara Balestrieri; Hannah Raff; Joshua A Boyce
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

5.  EP4 receptor promotes invadopodia and invasion in human breast cancer.

Authors:  Felix Tönisen; Louisiane Perrin; Battuya Bayarmagnai; Koen van den Dries; Alessandra Cambi; Bojana Gligorijevic
Journal:  Eur J Cell Biol       Date:  2017-01-10       Impact factor: 4.492

6.  Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis.

Authors:  Hu Xu; Bingying Fang; Shengnan Du; Sailun Wang; Qingwei Li; Xiao Jia; Chengzhen Bao; Lan Ye; Xue Sui; Lei Qian; Zhilin Luan; Guangrui Yang; Feng Zheng; Nanping Wang; Lihong Chen; Xiaoyan Zhang; Youfei Guan
Journal:  JCI Insight       Date:  2020-07-09

7.  PGE2 /EP4 receptor attenuated mucosal injury via β-arrestin1/Src/EGFR-mediated proliferation in portal hypertensive gastropathy.

Authors:  Siwei Tan; Xiaoliang Chen; Minyi Xu; Xiaoli Huang; Huiling Liu; Jie Jiang; Yu Lu; Xiaojie Peng; Bin Wu
Journal:  Br J Pharmacol       Date:  2017-03-25       Impact factor: 8.739

Review 8.  Pathology and molecular mechanisms of coarctation of the aorta and its association with the ductus arteriosus.

Authors:  Utako Yokoyama; Yasuhiro Ichikawa; Susumu Minamisawa; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2016-12-20       Impact factor: 2.781

9.  Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Yueqin Liu; Asuncion Martinez-Anton; Hai-Yan Qi; Carolea Logun; Sara Alsaaty; Yong Hwan Park; Daniel L Kastner; Jae Jin Chae; James H Shelhamer
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.